ONCOIMMUNITY
OncoImmunity has become the first company to obtain a CE-IVD mark for the clinical use of a machine-learning based neoantigen prediction technology. This quality assurance certification represents an important step in raising the standards for the use of neoantigen prediction technologies for the design of personalized cancer vaccines and cell therapies.
The certification means that personalized cancer vaccine and cell therapy companies can now meet their own quality assurance requirements for their clinical development by leveraging OncoImmunity’s proven quality assurance methodology. OncoImmunity’s neoantigen prediction technology, known as the Immuneoprofiler™, allows cancer immunotherapy companies to gain access to a quality assured prediction technology that also has superior performance in predicting the presentation of neoantigens to the tumor cell surface.
Richard Stratford CEO at OncoImmunity said:
“At OncoImmunity we understand intimately the complexity of neoantigen prediction and the need to select neoantigens for personalized cancer immunotherapy to a high clinical standard. We have designed machine-learning solutions to fill some of the gaps in the neoantigen prediction challenge and this certification of the Immuneoprofiler™ will facilitate both cost-saving and time-efficient filing for the accreditation of our partners cancer immunotherapy platforms”
About CE-IVD
The CE-mark (CE-IVD) indicates that an IVD device complies with the European In Vitro Diagnostics Directive (98/79/EC), and that the device may be legally commercialized and distributed in the EU.
About OncoImmunity
OncoImmunity is a machine-learning company offering a proprietary technology to address the key knowledge gaps in the prediction of bona fide immunogenic neoantigens for personalized cancer immunotherapy. OncoImmunity's software facilitates effective patient selection for cancer immunotherapy and identifies neoantigen targets for truly personalized cancer vaccines & cell therapies in a clinically actionable time-frame.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190311005667/en/
Contact:
Trevor Clancy Ph.D. CSO OncoImmunity E-mail: trevor@oncoimmunity.com Phone: + 47 41 43 12 42
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Red Sea Global Announces the Opening of AMAALA: The World’s New Coastal Lifestyle Destination11.11.2025 16:30:00 CET | Press release
With spectacular resorts, an exclusive yacht club, and world-leading marine life institute, RSG’s latest destination sets new global standards for holistic wellness and environmental stewardship Red Sea Global (RSG), the real estate developer and pioneer of regenerative tourism, announced the highly anticipated opening of AMAALA Triple Bay during the inaugural TOURISE Summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111682859/en/ Sea meets land: The world class AMAALA Triple Bay Marina Yacht Club on the Saudi Red Sea coastline Nestled across three naturally occurring bays on Saudi Arabia’s rugged north-western coast where the Hijaz Mountains meet the Red Sea, the ultra-luxury, wellness destination is set to open in the coming months. “Deriving from the Arabic word for hope, AMAALA offers a new coastal lifestyle rooted in wellness right here in Saudi Arabia. Guests and residents are invited to discover and honor what
Xsolla and Airbridge Partner to Deliver Unified Mobile and Web Performance Insights for Game Developers11.11.2025 15:36:00 CET | Press release
A New S2S Integration Connects Mobile and Web Data, Empowering Developers with a Unified View of Player Value and Marketing Performance Xsolla, a global commerce company helping developers launch, grow, and monetize their games, today announced a new mobile-focused Server-to-Server (S2S) integration with Airbridge, a leading unified measurement platform for mobile marketers. This strategic partnership empowers mobile game developers with precise, cross-platform performance tracking by bridging the gap between mobile marketing efforts and purchases made through the Xsolla Web Shop. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111170674/en/ (Graphic: Xsolla) As more developers turn to Web Shops to drive direct-to-consumer monetization beyond traditional app stores, understanding the full value of those off-platform transactions has become increasingly critical. With Xsolla’s new S2S integration, powered by Airbridge, deve
ThreatDown Launches Nexus Partner Program, Strengthening its Channel-First Commitment11.11.2025 15:02:00 CET | Press release
New program marks a strategic investment, putting partners at the center of ThreatDown’s growth strategy ThreatDown, the corporate business unit of Malwarebytes, today announced the launch of the Nexus Partner Program, a comprehensive initiative that puts partners at the center by strengthening collaboration and creating new growth opportunities for its global network of partners. The program aligns incentives, simplifies enablement, and strengthens collaboration to ensure every reseller has the resources and support needed to deliver smarter, stronger security outcomes for customers. “At ThreatDown, being channel-first means putting our partners at the center of everything we do,” says Kendra Krause, General Manager of ThreatDown. “The Nexus Partner Program reflects that belief – the program is built to equip partners with the tools they need to succeed in a rapidly evolving cybersecurity market. When our partners win, we win.” Available globally, the program offers competitive discou
Blue Matter Enhances Twine™ Platform Capabilities in Response to Growing Demand11.11.2025 15:01:00 CET | Press release
Blue Matter today announced the expansion of its Twine™ data platform’s capabilities in response to accelerating demand from biopharma companies. Enhancements include thoughtful use of artificial intelligence (AI) for advanced analytics and narratives, expanded data source integrations, master data management, and broader deployment across oncology and specialty therapeutic areas. Twine™ is Blue Matter's purpose-built customer intelligence platform for healthcare and life sciences companies. It transforms complex data from disparate sources including specialty pharmacy networks, hub services, claims databases, and other third party data sources into actionable insights that drive commercial strategy and operational excellence. With generative AI at its core, Twine helps companies more effectively acquire, master, validate, and analyze data from internal and third-party sources. Persona-specific outputs enable faster, more informed decision-making. According to Deepak Gopinath, Partner
Financial Sector Signals Rising Investment in Identity Verification11.11.2025 15:00:00 CET | Press release
Banks, fintechs, and crypto platforms are ramping up investment in fraud prevention and identity verification (IDV), positioning it as the next layer of cyber defense. According to Regula’s global survey, The Future of Identity Verification: 5 Threats and 5 Opportunities, banks are leading this trend: the share of institutions intending to increase IDV budgets by more than 50% is nearly tripling—from 4.4% to 15% in just two years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111008888/en/ Banks lead the IDV investment surge, but fintech, crypto, and aviation sectors are catching up fast, with roughly one in six companies planning to expand IDV budgets by more than 50%. Even healthcare is joining the trend, signaling how essential verification has become beyond finance. Moderate increases in identity verification budgets are becoming common across all financial services. Roughly a third of banks and crypto firms and a fi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom